Why most randomized phase II cervical cancer chemoprevention trials are uninformative: lessons for the future.
Follen
M
M
Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. mfollen@manderson.org
Meyskens
F L
FL
Atkinson
E N
EN
Schottenfeld
D
D
D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D001706:Biopsy; D002294:Carcinoma, Squamous Cell / Q000517:prevention & control; D017322:Clinical Trials, Phase II as Topic; D003127:Colposcopy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care; D027383:Papillomaviridae / Q000302:isolation & purification; D011237:Predictive Value of Tests; D012372:ROC Curve; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D012680:Sensitivity and Specificity; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000517:prevention & control
D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor